Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Tessa Y. S. Le Large

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4273-7217; OpenAlex author ID A5030588716. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 24

  1. Eph receptors in pancreatic cancer: Biological roles and clinical implications. Co-author DOI 10.1016/j.critrevonc.2026.105299↗
  2. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  3. In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations. Co-author DOI 10.1111/cas.16147↗
  4. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers. Co-author DOI 10.1001/jamanetworkopen.2023.31197↗
  5. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: A meta-analysis of aggregate and individual participant data. Co-author DOI 10.1016/j.eclinm.2022.101747↗
  6. Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer Co-author DOI 10.1101/2023.03.19.533333↗
  7. hENT1 as a Predictive Biomarker in PDAC-Letter. Co-author DOI 10.1158/1078-0432.ccr-22-3827↗
  8. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  9. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel A… Co-author DOI 10.3390/cancers14020344↗
  10. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response-Letter. Co-author DOI 10.1158/1078-0432.ccr-21-0775↗
  11. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-01892-z↗
  12. Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. Co-author DOI 10.1007/s13402-020-00548-y↗
  13. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003084↗
  14. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. Co-author DOI 10.1172/jci.insight.138290↗
  15. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Co-author DOI 10.1634/theoncologist.2019-0680↗
  16. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Co-author DOI 10.1177/1758835919841233↗
  17. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Co-author DOI 10.1016/j.semcancer.2017.03.008↗
  18. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. First author DOI 10.1007/978-1-4939-3347-1_10↗
  19. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Co-author DOI 10.1080/14737159.2016.1175940↗
  20. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i31.6987↗
  21. Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. Co-author DOI 10.1038/ajg.2015.77↗
  22. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Co-author DOI 10.1586/14737159.2015.1112273↗
  23. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. First author DOI 10.1155/2014/678401↗
  24. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 23 shared papers, 2014–2026 · strength 2.76
  2. Geert Kazemier M · 21 shared papers, 2015–2026 · strength 2.67
  3. Laura L. Meijer · 13 shared papers, 2015–2024 · strength 1.49
  4. Lenka N.C. Boyd · 8 shared papers, 2020–2024 · strength 1.30
  5. Hanneke W.M. van Laarhoven · 10 shared papers, 2017–2024 · strength 1.29
  6. Maarten F. Bijlsma · 8 shared papers, 2016–2022 · strength 0.75
  7. Adam Enver Frampton · 7 shared papers, 2014–2024 · strength 0.67
  8. Jisce R. Puik · 4 shared papers, 2022–2024 · strength 0.65
  9. Ingrid Garajová · 6 shared papers, 2014–2024 · strength 0.61
  10. Niccola Funel · 7 shared papers, 2014–2021 · strength 0.60
  11. Connie R. Jiménez · 6 shared papers, 2017–2021 · strength 0.57
  12. Godefridus J. Peters · 4 shared papers, 2014–2026 · strength 0.52
  13. Marc G. Besselink · 3 shared papers, 2023–2024 · strength 0.50
  14. Luca Morelli · 3 shared papers, 2021–2024 · strength 0.43
  15. Karlijn A. van de Langerijt · 1 shared paper, 2026 · strength 0.36
  16. Annalisa Comandatore · 2 shared papers, 2023–2024 · strength 0.32
  17. Eline S. Zwart · 2 shared papers, 2022–2024 · strength 0.32
  18. Yvette van Kooyk · 2 shared papers, 2022–2024 · strength 0.30
  19. Ernesto Rodríguez · 2 shared papers, 2022–2024 · strength 0.30
  20. Freek D. Daams · 2 shared papers, 2020–2022 · strength 0.23
  21. Babs M. Zonderhuis · 2 shared papers, 2020–2022 · strength 0.23
  22. Kenneth P. Olive · 2 shared papers, 2019–2023 · strength 0.22
  23. Andrea Mambrini · 2 shared papers, 2014–2024 · strength 0.21
  24. Btissame El Hassouni · 2 shared papers, 2019–2021 · strength 0.19
  25. Chiara Caparello · 2 shared papers, 2016–2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.